Research Analysts Offer Predictions for MIRM Q2 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for Mirum Pharmaceuticals in a report released on Monday, May 19th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.36) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $73.00 target price on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at $0.44 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $2.09 EPS.

Several other analysts have also commented on MIRM. JMP Securities increased their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research report on Friday, May 9th. Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. Finally, Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $60.73.

Mirum Pharmaceuticals Stock Down 0.1%

Shares of MIRM stock traded down $0.05 during mid-day trading on Wednesday, hitting $44.00. 164,520 shares of the stock traded hands, compared to its average volume of 522,623. The stock has a market cap of $2.18 billion, a P/E ratio of -21.78 and a beta of 0.95. The stock's fifty day moving average is $42.95 and its two-hundred day moving average is $44.59. Mirum Pharmaceuticals has a 52-week low of $23.83 and a 52-week high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. During the same period in the prior year, the firm earned ($0.54) earnings per share. The firm's revenue for the quarter was up 61.2% compared to the same quarter last year.

Insider Activity

In related news, CEO Christopher Peetz sold 27,279 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the transaction, the chief executive officer now owns 138,641 shares in the company, valued at approximately $6,129,318.61. This represents a 16.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jolanda Howe sold 57,606 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the completion of the transaction, the senior vice president now owns 4,841 shares in the company, valued at approximately $214,698.35. This trade represents a 92.25% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,764 shares of company stock worth $4,109,161 over the last 90 days. 14.36% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in MIRM. Barclays PLC lifted its position in shares of Mirum Pharmaceuticals by 4.6% during the 3rd quarter. Barclays PLC now owns 245,918 shares of the company's stock valued at $9,592,000 after buying an additional 10,824 shares in the last quarter. Secure Asset Management LLC lifted its position in shares of Mirum Pharmaceuticals by 9.3% during the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company's stock valued at $1,651,000 after buying an additional 3,406 shares in the last quarter. R Squared Ltd purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at approximately $69,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Mirum Pharmaceuticals by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock valued at $421,000 after buying an additional 1,003 shares in the last quarter. Finally, Golden State Equity Partners lifted its position in shares of Mirum Pharmaceuticals by 1,390.8% during the 4th quarter. Golden State Equity Partners now owns 19,380 shares of the company's stock valued at $801,000 after buying an additional 18,080 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.